Momentum for Goodlatte Innovation Act slipping away?
The House should give the system time to adjust to the 2011 reforms before moving forward on another set of transformational reforms," the group's director said in a statement. "Heritage Action opposes H.R. 9. The bill should not come to the floor.”
Elsewhere, there are proposed changes to inter partes review:
Lobbyists for the biotechnology and pharmaceutical industry are fighting to include a provision that would exempt some FDA-approved drug patents from the U.S. Patent and Trademark Office's trial-like reviews, which were set up as a fast and low-cost way to challenge the validity of patents. But some seniors groups have opposed that inclusion.
See also the post by former Congressman Ron Klink (D-Pa.)